NeuroVision is an integrated neuroscience company focused on delivering scientifically validated diagnostic tests & biomarkers for early detection and monitoring of neurologic and ophthalmic disorders.  With access to unique datasets, we provide data aggregation services, analysis, biostatistics, and applications of machine learning algorithms to large repositories of images and other biomarker data seeking to advance the collective understanding and prediction capabilities for neurodegenerative diseases.

There is a significant unmet need for a cost-effective, noninvasive test that can be applied to large segments of the at-risk population for preclinical Alzheimer’s Disease (AD) and AD dementia. A noninvasive test to detect the primary pathological sign of AD at an early stage is essential for cost-effective screening, diagnosis, and monitoring treatment. NeuroVision is pursuing two initiatives to address this unmet need.  The first initiative is in blood biomarkers.  We are developing multiple assays with ultra-high sensitivity and multiplex capability for use in Alzheimer's Disease diagnostics and disease progression.  The second initiative is the identification and direct measurement of amyloid-β protein (Aβ) plaques, the characteristic of AD pathology, in the retina of live human test subjects consisting of heathy controls, MCI and AD, versus amyloid PET and the gold-standard postmortem evaluation of amyloid in the brain.

We also seek to leverage our retinal image analysis expertise to develop and to commercialize tools to aid eye care professionals in the early identification of vision-threatening retinal disease and diseases that manifest in the retina.